Analyst Ratings For Cytokinetics, Incorporated (NASDAQ:CYTK)
Today, Morgan Stanley initiated coverage on Cytokinetics, Incorporated (NASDAQ:CYTK) with a Overweight with a price target of $24.00.
There are 9 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on Cytokinetics, Incorporated (NASDAQ:CYTK) is Buy (Score: 3.10) with a consensus target price of $21.40 per share, a potential 52.31% upside.
Some recent analyst ratings include
- 7/31/2017-Morgan Stanley initiated coverage with a Overweight rating.
- 5/19/2017-Cantor Fitzgerald Reiterated Rating of Overweight.
- 4/29/2017-Cowen and Company Reiterated Rating of Outperform.
- 4/25/2017-HC Wainwright Reiterated Rating of Buy.
- 3/23/2017-Rodman & Renshaw Reiterated Rating of Buy.
- 2/17/2017-FBR & Co Reiterated Rating of Outperform.
- 2/17/2017-Needham & Company LLC Reiterated Rating of Strong-Buy.
Recent Insider Trading Activity For Cytokinetics, Incorporated (NASDAQ:CYTK)
Cytokinetics, Incorporated (NASDAQ:CYTK) has insider ownership of 7.20% and institutional ownership of 59.65%.
- On 7/3/2017 Robert I Blum, CEO, sold 5,000 with an average share price of $12.14 per share and the total transaction amounting to $60,700.00. View SEC Filing
- On 6/1/2017 Robert I Blum, CEO, sold 5,000 with an average share price of $13.62 per share and the total transaction amounting to $68,100.00. View SEC Filing
- On 12/29/2016 Fady Ibraham Malik, EVP, sold 5,633 with an average share price of $12.36 per share and the total transaction amounting to $69,623.88. View SEC Filing
- On 8/31/2015 L Patrick Gage, Director, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00. View SEC Filing
- On 8/20/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $6.55 per share and the total transaction amounting to $65,500.00. View SEC Filing
- On 5/6/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $5.71 per share and the total transaction amounting to $57,100.00. View SEC Filing
- On 3/11/2015 Andrew A Wolff, CMO, sold 21,875 with an average share price of $7.80 per share and the total transaction amounting to $170,625.00. View SEC Filing
Recent Trading Activity for Cytokinetics, Incorporated (NASDAQ:CYTK)
Shares of Cytokinetics, Incorporated closed the previous trading session at 14.05 down -0.15 -1.06% with 188,988 shares trading hands.